期刊文献+

骨科医院门诊2011年非甾体抗炎药应用情况分析 被引量:7

下载PDF
导出
摘要 目的了解该院门诊非甾体抗炎药的使用情况,为临床合理、有效、经济地选用该类药物提供理论依据。方法采用回顾性调查的方法,对骨科医院2011年1~12月含非甾体抗炎药的处方75 480张处方进行统计分析。结果选择性环氧化酶-2抑制剂塞来昔布的用药频度排第一,广泛应用于缓解骨关节炎和成人类风湿关节炎的症状和体征。目前临床非甾体类药当中存在个别配伍不合理的地方。结论非甾体抗炎药用药过程必须保持高度警惕,严密监测心、肝、肾、胃肠道等的功能,并加强不良反应的监测。
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2013年第25期106-108,共3页 China Journal of Modern Medicine
  • 相关文献

二级参考文献12

  • 1BOMBARDIER C, LAINE L, REICIN A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group[ J]. N Engl J Med, 2000, 343(21 ) :1520 - 1528.
  • 2SCHNITZER TJ, BURMESTER GR, MYSLER E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial[ J]. Lancet, 2004, 364(9435 ) :665 - 674.
  • 3SILVERSTEIN FE, FAICH G, GOLDSTEIN JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS stud- y: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study[ J]. JAMA, 2000, 284 (10) : 1247 - 1255.
  • 4LAINE L, CURTIS SP, CRYER B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [ J ]. Lancet, 2007, 369 (9560) :465 - 473.
  • 5BRESALIER RS, SANDLER RS, QUAN H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma che- moprevention trial[ J ]. N Engl J Med, 2005, 352 (11 ) :1092 - 1102.
  • 6BERTAGNOLLI MM, EAGLE C J, ZAUBER AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas [ J ]. N Engl J Med, 2006, 355 ( 9 ) :873 - 884.
  • 7KEARNEY PM, BAIGENT C, GODWIN J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials [ J]. BMJ, 2006, 332 (7553) : 1302 - 1308.
  • 8MCGETTIGAN P, HENRY D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 [J]. JAMA, 2006, 296(13): 1633 -1644.
  • 9HINZ B, RENNER B, BRUNE K. Drug insight: cyclo-oxygenase-2 inhibitors a critical appraisal [ J ]. Nat Clin Pract Rheumatol, 2007, 3 (10) :552 - 560.
  • 10ZANCHETTI A, HANSSON L, DAHLOF B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group[ J]. J Hypertens, 2001, 19 (6) :1149 - 1159.

共引文献10

同被引文献92

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部